Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | WRN | Q14191 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27275549 | 0.93 | GSK3A (0.46) | GSK3AGSK3BMGLLALDH1A1BLM | |
| SCHEMBL34462063 | 0.83 | GSK3A (0.47) | GSK3AGSK3BMGLLALDH1A1BLM | |
| SCHEMBL30831357 | 0.81 | GSK3A (0.40) | GSK3AGSK3BMGLLALDH1A1BLM | |
| SCHEMBL2754833 | 0.81 | PTGS1 (0.44) | GSK3AGSK3BMGLLALDH1A1BLM | |
| SCHEMBL20287639 | 0.81 | GSK3A (0.44) | GSK3AGSK3BMGLLALDH1A1BLM | |
| SCHEMBL21518574 | 0.80 | GSK3A (0.45) | GSK3AGSK3BMGLLALDH1A1BLM | |
| SCHEMBL15490342 | 0.79 | GSK3B (0.43) | GSK3AGSK3BMGLLALDH1A1BLM | |
| SCHEMBL18101913 | 0.79 | GSK3A (0.47) | GSK3AGSK3BMGLLALDH1A1BLM | |
| SCHEMBL14327720 | 0.79 | GSK3A (0.43) | GSK3AGSK3BMGLLALDH1A1BLM | |
| SCHEMBL437306 | 0.79 | GSK3A (0.50) | GSK3AGSK3BMGLLALDH1A1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260077073-A1 | GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF | ALPHA 9 ONCOLOGY INC (CA) | 2026-03-19 | — | — | US | disclosed |
| US-20250195702-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-06-19 | — | — | US | disclosed |
| US-20250186627-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-06-12 | — | — | US | disclosed |
| US-20250161501-A1 | Radiolabeled Compounds for Imaging of Fibroblast Activation Protein (FAP) and Treatment of FAP-Related Disorders | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-05-22 | — | — | US | disclosed |
| WO-2025054727-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-03-20 | — | — | WO | disclosed |
| US-12246076-B2 | Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-03-11 | — | — | US | disclosed |
| EP-4499663-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | Provincial Health Services Authority (CA) | 2025-02-05 | — | — | EP | disclosed |
| EP-4486756-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | Provincial Health Services Authority (CA) | 2025-01-08 | — | — | EP | disclosed |
| US-20240123099-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-04-18 | — | — | US | disclosed |
| WO-2023178449-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2023-09-28 | — | — | WO | disclosed |
| US-20140057303-A1 | Antibodies to Olanzapine Haptens and Use Thereof | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-27 | — | — | US | disclosed |
| US-20140057299-A1 | Antibodies to Aripiprazole Haptens and Use Thereof | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-27 | — | — | US | disclosed |
| US-20130122024-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-20130095123-A1 | New binder-drug conjugates (ADCs) and use thereof | Bayer Pharma AG (DE) | 2013-04-18 | — | — | US | disclosed |
| US-20130066055-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
| EP-2235044-A1 | NEW POLYPEPTIDES HAVING AFFINITY FOR HER2 | Affibody AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-20090175821-A1 | Modified therapeutic peptides with extended half-lives in vivo | CONJUCHEM, LLC | 2009-07-09 | — | — | US | disclosed |
| WO-2009080810-A1 | NEW POLYPEPTIDES HAVING AFFINITY FOR HER2 | AFFIBODY AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| US-20090093408-A1 | Protection of exendin-4 peptides through conjugation | CONJUCHEM, LLC | 2009-04-09 | — | — | US | disclosed |
| US-7256253-B2 | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components | CONJUCHEM BIOTECHNOLOGIES INC. (CA) | 2007-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186627-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | FSHR, ESRRA, ESRRG | GSK3A 4775/4885GSK3B 4655/4885MGLL 4201/4885 |
| US-20130122024-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | MDN1, EPCAM, VCAM1 | GSK3A 3411/4885GSK3B 3188/4885MGLL 3886/4885 |
| US-20130066055-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | CDK4, CDKL4, FLT4 | GSK3A 3316/4885GSK3B 3225/4885MGLL 4667/4885 |
| US-20090175821-A1 | Modified therapeutic peptides with extended half-lives in vivo | DNPEP, ANPEP, ENPEP | GSK3A 4481/4885GSK3B 4584/4885MGLL 1892/4885 |
| US-20250161501-A1 | Radiolabeled Compounds for Imaging of Fibroblast Activation Protein (FAP) and Treatment of FAP-Related Disorders | FAP, FIBP, FGFR1 | GSK3A 4661/4885GSK3B 4626/4885MGLL 3061/4885 |
| US-20140057303-A1 | Antibodies to Olanzapine Haptens and Use Thereof | HTR4, HTR3C, HTR1A | GSK3A 868/4885GSK3B 1078/4885MGLL 3583/4885 |
| US-12246076-B2 | Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders | GRPR, NPY5R, NPY2R | GSK3A 1498/4885GSK3B 2258/4885MGLL 3505/4885 |
| US-20240123099-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | GRPR, NPY5R, NPY2R | GSK3A 1498/4885GSK3B 2258/4885MGLL 3505/4885 |
| US-20140057299-A1 | Antibodies to Aripiprazole Haptens and Use Thereof | FCER2, HTR4, HTR3C | GSK3A 1090/4885GSK3B 1509/4885MGLL 4042/4885 |
| US-20130095123-A1 | New binder-drug conjugates (ADCs) and use thereof | CDK4, CDKL4, FLT4 | GSK3A 3316/4885GSK3B 3225/4885MGLL 4667/4885 |
| US-20250195702-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | GRPR, NPY5R, NPY2R | GSK3A 1579/4885GSK3B 2311/4885MGLL 3330/4885 |
| US-20090093408-A1 | Protection of exendin-4 peptides through conjugation | VIP, PEPD, ANPEP | GSK3A 4275/4885GSK3B 4361/4885MGLL 2195/4885 |
| US-20260077073-A1 | GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF | GRPR, GIPR, GLP1R | GSK3A 2693/4885GSK3B 3370/4885MGLL 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.